AABB is the voice of the blood and cellular therapies community before the Food and Drug Administration and FDA advisory committees, such as the Blood Products Advisory Committee and Cellular, Tissue, and Gene Therapies Advisory Committee. The Association engages stakeholders within AABB's membership and the broader community to develop materials that provide FDA with the community’s position on draft guidances, proposed regulations and policies, and research priorities. These AABB-led efforts create an important dialogue with federal regulators that helps promote a strong and safe supply of blood and cells.
FDA Announces More Flexible Approach to CGT Regulation
January 13, 2026
REGULATORY UPDATE: FDA Releases 2026 CBER Guidance Agenda
January 12, 2026
FDA Approves First Oral Anemia Treatment for Thalassemia
January 07, 2026
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
